System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Cosimo De Nunzio, MD, PhD is an expert in Urology at Azienda Ospedaliera Sant'Andrea (Italy). As of October 2026, ScienceLeadR ranks Cosimo De Nunzio in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. Cosimo De Nunzio has authored 663 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 3 of them ongoing. SLR score: 2,167 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Cosimo De Nunzio, MD, PhD Azienda Ospedaliera Sant'Andrea Italy
2 167 ScienceLeadR Reputation 2167

Unlock

Register Login
Network Map

Urology

Subspecialties: Oncology - Surgery - Nephrology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Sapienza University of Rome

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 663

Citations

Citations: 14 183 1st author: 146 Last author: 134 Unique author: 3

Main journals

J Urol 76
Prostate Cancer Prostatic Dis 72
Minerva Urol Nefrol 48
Minerva Urol Nephrol 42
Eur Urol 39

Best Journals

JAMA 2
Ann Oncol 1
J Clin Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prostate cancer worldwide: updated epidemiology, disparities, and screening implications.
PMID 42946767 — epidemiology, neoplasms, prostate, biomarkers, prostatic neoplasms		Prostate Cancer Prostatic Dis20260
Cribriform and intraductal carcinoma in prostate cancer - implications for risk stratification and therapeutic decision-making.
PMID 42855542 — neoplasms, prostate, decision making, biomarkers, carcinoma, intraductal, noninfiltrating, prostatic neoplasms, therapeutics		Nat Rev Urol20260
Development of a ChatGPT-based assistant in multidisciplinary team discussions in oncological urology: the UroMDT Advisor study.
PMID 42804130 — kidney diseases, urology, radiation oncologists, oncologists, urologists, generative artificial intelligence		Int Urol Nephrol20260
Comparable is not equivalent in short-term optilume evaluation.
PMID 42789106 — urology		World J Urol20260
PHI for adverse pathology and PHI density for upgrading: two complementary predictors in localized prostate cancer.
PMID 42778618 — neoplasms, pathology, prostate, biopsy, biomarkers, prostatic neoplasms		Prostate Cancer Prostatic Dis20260

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 3
Phase 2 1
Phase 3 1
Phase 4 1

By status:

Recruiting 3
Unknown 3

By type:

Interventional 3
Observational 3

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and staged as oligometastatic with PSMA PET (STAPLE)
2024-515049-41-00 — neoplasms, prostate, prostatic neoplasms, therapeutics, prostatectomy		Phase 2Recruiting2024
Tensi European Post Market Clinical Follow Up
NCT07205445 — urinary bladder, urology, safety, transcutaneous electric nerve stimulation, tibial nerve, urinary bladder, overactive		N/ARecruiting2025
BPH Global Registry
NCT05543200 — registries, urinary tract, signs and symptoms, prostatic hyperplasia, lower urinary tract symptoms, therapeutics, hyperplasia		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS